IM Cannabis Corp. (IMCC)
USD 1.73
(2.37%)
USD 1.73
(2.37%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 9.84 Million CAD | -25.16% |
| 2022 | 9.16 Million CAD | -11.01% |
| 2021 | 10.29 Million USD | -1.64% |
| 2020 | 10.46 Million CAD | 166.43% |
| 2019 | 3.92 Million CAD | -6.41% |
| 2018 | 4.19 Million CAD | 49.77% |
| 2017 | 2.8 Million CAD | 0.0% |
| 2016 | - CAD | 100.0% |
| 2015 | -514.00 CAD | 90.84% |
| 2014 | -5611.00 CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| 2005 | - CAD | 0.0% |
| 2004 | - CAD | 0.0% |
| 2003 | - CAD | -100.0% |
| 2002 | 34.58 Thousand CAD | 0.0% |
| 2001 | 34.58 Thousand CAD | -68.81% |
| 2000 | 110.89 Thousand CAD | 10.89% |
| 1999 | 100 Thousand CAD | 0.0% |
| 1998 | 100 Thousand CAD | -83.33% |
| 1997 | 600 Thousand CAD | -45.45% |
| 1996 | 1.1 Million CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 844 Thousand CAD | -52.56% |
| 2024 Q1 | 1.77 Million CAD | 111.53% |
| 2023 Q3 | 9 Million CAD | 160.56% |
| 2023 Q2 | 3.45 Million CAD | -2.59% |
| 2023 FY | 6.85 Million CAD | -25.16% |
| 2023 Q4 | 841 Thousand CAD | -90.66% |
| 2023 Q1 | 3.54 Million CAD | 36.3% |
| 2022 Q2 | 4.01 Million CAD | -38.89% |
| 2022 Q1 | 6.57 Million CAD | 52.4% |
| 2022 FY | 9.16 Million CAD | -11.01% |
| 2022 Q4 | 2.6 Million CAD | 33.28% |
| 2022 Q3 | 1.95 Million CAD | -51.36% |
| 2021 Q1 | 5.02 Million CAD | 891.72% |
| 2021 Q4 | 4.31 Million USD | 182.69% |
| 2021 Q2 | -568 Thousand CAD | -111.3% |
| 2021 FY | 10.29 Million USD | -1.64% |
| 2021 Q3 | 1.52 Million CAD | 368.49% |
| 2020 Q1 | -1.91 Million CAD | -597.81% |
| 2020 FY | 10.46 Million CAD | 166.43% |
| 2020 Q2 | 1.98 Million CAD | 203.97% |
| 2020 Q4 | 507 Thousand CAD | -85.0% |
| 2020 Q3 | 3.38 Million CAD | 70.07% |
| 2019 Q1 | 1.3 Million CAD | 324.1% |
| 2019 Q4 | -274 Thousand CAD | -143.01% |
| 2019 Q3 | 637 Thousand CAD | -71.86% |
| 2019 FY | 3.92 Million CAD | -6.41% |
| 2019 Q2 | 2.26 Million CAD | 73.89% |
| 2018 Q2 | -36 Thousand CAD | -103.56% |
| 2018 Q4 | 307 Thousand CAD | 5.5% |
| 2018 Q1 | 1.01 Million CAD | 0.0% |
| 2018 FY | 4.19 Million CAD | 49.77% |
| 2018 Q3 | 291 Thousand CAD | 908.33% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 FY | 2.8 Million CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2016 FY | - CAD | 100.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2015 FY | -514.00 CAD | 90.84% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | -5611.00 CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2006 Q4 | - CAD | 0.0% |
| 2006 Q3 | - CAD | 0.0% |
| 2006 FY | - CAD | 0.0% |
| 2006 Q1 | - CAD | 0.0% |
| 2006 Q2 | - CAD | 0.0% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q4 | - CAD | 0.0% |
| 2005 Q3 | - CAD | 0.0% |
| 2005 Q2 | - CAD | 0.0% |
| 2005 Q1 | - CAD | 0.0% |
| 2004 Q1 | - CAD | 0.0% |
| 2004 FY | - CAD | 0.0% |
| 2004 Q2 | - CAD | 0.0% |
| 2004 Q3 | - CAD | 0.0% |
| 2004 Q4 | - CAD | 0.0% |
| 2003 Q2 | - CAD | 0.0% |
| 2003 Q3 | - CAD | 0.0% |
| 2003 Q1 | - CAD | 0.0% |
| 2003 FY | - CAD | -100.0% |
| 2003 Q4 | - CAD | 0.0% |
| 2002 FY | 34.58 Thousand CAD | 0.0% |
| 2002 Q3 | - CAD | 0.0% |
| 2002 Q1 | - CAD | -100.0% |
| 2002 Q4 | - CAD | 0.0% |
| 2002 Q2 | - CAD | 0.0% |
| 2001 Q4 | 9457.00 CAD | 29.55% |
| 2001 Q2 | 17.82 Thousand CAD | 172.53% |
| 2001 FY | 34.58 Thousand CAD | -68.81% |
| 2001 Q1 | 6541.00 CAD | -62.23% |
| 2001 Q3 | 7300.00 CAD | -59.05% |
| 2000 Q1 | - CAD | -100.0% |
| 2000 Q4 | 17.31 Thousand CAD | 1731800.0% |
| 2000 Q3 | 1.00 CAD | -100.0% |
| 2000 Q2 | 100 Thousand CAD | 0.0% |
| 2000 FY | 110.89 Thousand CAD | 10.89% |
| 1999 Q3 | 100 Thousand CAD | 0.0% |
| 1999 FY | 100 Thousand CAD | 0.0% |
| 1999 Q4 | 100 Thousand CAD | 0.0% |
| 1999 Q2 | 100 Thousand CAD | 200.0% |
| 1999 Q1 | -100 Thousand CAD | -200.0% |
| 1998 Q3 | 100 Thousand CAD | 0.0% |
| 1998 FY | 100 Thousand CAD | -83.33% |
| 1998 Q4 | 100 Thousand CAD | 0.0% |
| 1998 Q1 | -100 Thousand CAD | -133.33% |
| 1998 Q2 | 100 Thousand CAD | 200.0% |
| 1997 Q3 | 200 Thousand CAD | 100.0% |
| 1997 Q2 | 100 Thousand CAD | 0.0% |
| 1997 FY | 600 Thousand CAD | -45.45% |
| 1997 Q4 | 300 Thousand CAD | 50.0% |
| 1996 FY | 1.1 Million CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 96.775% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 66.906% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 96.981% |
| Cosmos Health Inc. | 4.34 Million USD | -126.367% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 508.518% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 86.525% |
| Cronos Group Inc. | 6.99 Million USD | -40.84% |
| Incannex Healthcare Limited | 12 Thousand USD | -81950.0% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 3349.505% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 76.473% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 1420.568% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -18.069% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -18.069% |
| SCYNEXIS, Inc. | 124.51 Million USD | 92.093% |
| Safety Shot Inc | -74.45 Thousand USD | 13323.74% |
| Theratechnologies Inc. | 62.12 Million USD | 84.152% |
| Alpha Teknova, Inc. | 10.29 Million USD | 4.371% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 2.301% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 97.992% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -107.503% |
| Dynavax Technologies Corporation | 182.11 Million USD | 94.594% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 97.768% |
| Radius Health, Inc. | 307.71 Million USD | 96.8% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -1677.349% |
| Alvotech | -69.42 Million USD | 114.183% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 97.714% |
| SIGA Technologies, Inc. | 122.09 Million USD | 91.936% |
| Shineco, Inc. | 882.16 Thousand USD | -1016.114% |
| Silver Spike Investment Corp. | 8.1 Million USD | -21.517% |
| Journey Medical Corporation | 52.52 Million USD | 81.253% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -134.923% |
| Embecta Corp. | 749.9 Million USD | 98.687% |
| Harrow Health, Inc. | 90.55 Million USD | 89.127% |
| Procaps Group, S.A. | 239.56 Million USD | 95.89% |
| Biofrontera Inc. | 16.62 Million USD | 40.783% |
| DURECT Corporation | 6.83 Million USD | -44.137% |
| PainReform Ltd. | -15 Thousand USD | 65740.0% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 98.12% |
| OptiNose, Inc. | 62.35 Million USD | 84.21% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -222.379% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 96.822% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 70.597% |
| ProPhase Labs, Inc. | 16.23 Million USD | 39.368% |
| Phibro Animal Health Corporation | 312.48 Million USD | 96.849% |
| Procaps Group S.A. | 239.56 Million USD | 95.89% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -656.221% |
| Viatris Inc. | 6.43 Billion USD | 99.847% |
| Rockwell Medical, Inc. | 8.7 Million USD | -13.12% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 81.962% |
| Tilray Brands, Inc. | 223.35 Million USD | 95.592% |
| PetIQ, Inc. | 252.74 Million USD | 96.104% |
| Talphera, Inc. | -4.89 Million USD | 301.144% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.467% |
| Alimera Sciences, Inc. | 61.17 Million USD | 83.904% |
| Assertio Holdings, Inc. | 125.04 Million USD | 92.126% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 144660.27% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 63.691% |
| Hempacco Co., Inc. | -1.21 Million USD | 909.815% |
| Alvotech | -69.42 Million USD | 114.183% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 98.612% |
| Kamada Ltd. | 52.59 Million USD | 81.279% |
| Currenc Group, Inc. | 17.35 Million USD | 43.271% |
| Indivior PLC | 907 Million USD | 98.914% |
| Evoke Pharma, Inc. | 4.97 Million USD | -97.76% |
| Flora Growth Corp. | 17.73 Million USD | 44.492% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 508.518% |
| Evolus, Inc. | 140.52 Million USD | 92.993% |
| HUTCHMED (China) Limited | 453.55 Million USD | 97.829% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 97.138% |
| Akanda Corp. | 111.44 Thousand USD | -8734.534% |